Summary
The anti-tumour effects and mechanism of action of combretastatin A-4 and its prodrug, combretastatin A-4 disodium phosphate, were examined in subcutaneous and orthotopically transplanted experimental colon tumour models. Additionally, the ability of these compounds to directly interfere with endothelial cell behaviour was also examined in HUVEC cultures. Combretastatin A-4 (150 mg kg–1, intraperitoneally (i.p.)) and its water-soluble prodrug (100 mg kg–1, i.p.) caused almost complete vascular shutdown (at 4 h), extensive haemorrhagic necrosis which started at 1 h after treatment and significant tumour growth delay in MAC 15A subcutaneous (s.c.) colon tumours. Similar vascular effects were obtained in MAC 15 orthotopic tumours and SW620 human colon tumour xenografts treated with the prodrug. More importantly, in the orthotopic models, necrosis was seen in vascularized metastatic deposits but not in avascular secondary deposits. The possible mechanism giving rise to these effects was examined in HUVEC cells. Here cellular networks formed in type I calf-skin collagen layers and these networks were completely disrupted when incubated with a non-cytotoxic concentration of combretastatin A-4 or its prodrug. This effect started at 4 h and was complete by 24 h. The same non-cytotoxic concentrations resulted in disorganization of F-actin and β-tubulin at 1 h after treatment. In conclusion, combretastatin A-4 and its prodrug caused extensive necrosis in MAC 15A s.c. and orthotopic colon cancer and metastases, resulting in anti-tumour effects. Necrosis was not seen in avascular tumour nodules, suggesting a vascular mechanism of action.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baguley, BC, Holdaway, KM, Thomsen, LL, Zhuang, L & Zwi, LJ (1991). Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. Eur J Cancer 27: 482–487.
Bibby, MC, Double, JA, Loadman, PM & Duke, CV (1989a). Reduction of tumour blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst 81: 216–220.
Bibby, MC, Phillips, RM & Double, JA (1989b). Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512). Cancer Chemother Pharmacol 24: 87–94.
Bibby, MC, Double, JA, Phillips, RM & Quinn, PK (1991a). Flavone acetic acid: is vascular shutdown the crucial mechanism of action. Int J Radiat Biol 60: 395–399.
Bibby, MC, Phillips, RM, Double, JA & Pratesi, G (1991b). Anti-tumour activity of flavone acetic acid (NSC 347512) in mice – influence of immune status. Br J Cancer 63: 57–62.
Bibby, MC, Sleigh, NR, Loadman, PM & Double, JA (1993). Potentiation of EO9 antitumour activity by hydralazine. Eur J Cancer 29A: 1033–1035.
Birchmeier, W (1984). Cytoskeleton, structure and function. Trends Biochem Sci 9: 192–195.
Borenfreund, E, Babich, H & Martin-Alguacil, N (1990). A rapid chemosensitivity assay with human normal and tumour cells in vitro. In vitro Cell Dev Biol 26: 1030–1034.
Bujaski, A, Nowgrodzka Zagorska, M, Lenko, J & Miodonski, AJ (1989). Angiomorphology of human renal cell carcinoma. Virchows Archiv A Pathol Anat 415: 103–113.
Chabner, BA & Collins, JA (1990). Cancer Chemotherapy: Principles and Practice, JB Lippincott: Philadelphia
Chaplin, DJ, Peters, CE, Horsman, MR & Trotter, MJ (1991). Drug induced perturbations in tumour blood flow: therapeutic potential and possible limitations. Radiother Oncol 20: 93–101.
Ching, LM, Joseph, WR & Baguley, BC (1992). Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer 66: 128–130.
Clearkin, PA (1937). The effect of colchicine on normal and neoplastic tissues in mice. J Pathol Bact 44: 469–480.
Cowen, SE, Bibby, MC & Double, JA (1995). Characterisation of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies. Acta Oncol 34: 357–360.
Dark, GG, Hill, SA, Prise, VE, Tozer, GM, Pettit, GR & Chaplin, DJ (1997). Combretastatin A-4, an agent that displays potent and selective toxicity towards tumour vasculature. Cancer Res 57: 1829–1834.
Double, JA & Cifuentes de Castro, L (1978). Chemotherapy of transplantable adenocarcinomas of the colon in mice. II. Development and characterisation of an ascitic cell line. Cancer Treat Rep 62: 85–90.
Double, JA, Ball, CR & Cowen, PN (1975). Transplantation of adenocarcinomas of the colon in mice. J Natl Cancer Inst 54: 271–275.
Dvorak, HF, Nagy, JA, Dvorak, JT & Dvorak, AM (1988). Identification and characterization of the blood vessels of solid tumours that are leaky to circulating macromolecules. Am J Pathol 133: 95–109.
Egawa, J & Ishioka, K (1979). Construction of blood vessels in experimental tumours – some considerations on radioresistance. In:Treatment of Radioresistant Cancers, Abe M Sakamoto K Phillips TL Elsevier/North Holland Biomedical Press: Amsterdam 213–227.
Geran, RI, Greenberg, NH & MacDonald, MM (1972). Protocols for screening chemical agents and natural products against tumours and other biological systems (Third edition). Cancer Chemother Rep 3: 1–103.
Hill, SA, Sampson, LE & Chaplin, DJ (1995). Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 63: 119–123.
Jaffe, E, Nachman, R, Becker, C & Minick, C (1973). Culture of human endothelial cells derived from umbilical veins. J Clin Invest 52: 2745–2756.
Laws, AL, Matthew, AM, Double, JA & Bibby, MC (1995). Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 71: 1204–1209.
McGown, AT & Fox, BW (1989). Structural and biochemical comparison of the anti-mitotic agents cholchicine, combretastatin A-4 and amphethinile. Anti-Cancer Drug Des 3: 249–254.
Maciag, T, Kadish, J, Wilkins, L, Stemerman, MB & Weinstein, R (1982). Organizational behaviour of human umbilical vein endothelial cells. J Cell Biol 94: 511–520.
Mahadevan, V, Malik, STA, Meager, A, Fiers, W, Lewis, GP & Hart, IR (1990). Role of tumour necrosis factor in flavone-acetic acid-induced tumour vasculature shutdown. Cancer Res 50: 5537–5542.
Montesano, R, Orci, L & Vassalli, P (1983). In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97: 1648–1652.
Pettit, GR, Singh, SB, Hamel, E, Lin, CM, Alberts, DS & Garcia-Kendall, D (1989). Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45: 209–211.
Pettit, GR, Temple, CJR, Nnarayanan, VL, Varma, R, Simpson, MJ, Boyd, MR, Rener, GA & Bansal, NN (1995). Antineoplastic agent 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10: 299–309.
Rewcastle, GW, Atwell, GJ, Baguley, BC, Calveley, SB & Denny, WA (1989). Potential antitumour agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the Colon 38 tumour in vivo. J Med Chem 32: 793–799.
Rowinsky, EK, Cazenave, LA & Donehower, RC (1990). Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247–1259.
Schiff, PB & Horwitz, SB (1980). Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561–1565.
Schiff, PB, Fant, J & Horwitz, SB (1979). Promotion of microtubule assembly in vitro by taxol. Nature 22: 665–667.
Schor, AM, Schor, SL & Allen, TD (1983). Effects of culture conditions on the proliferation, morphology and migration of bovine aortic endothelial cells. J Cell Science 62: 267–285.
Smith, KA, Hill, SA, Begg, AC & Denekamp, J (1988). Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 57: 247–253.
UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia (1998). Br J Cancer 77: 1–10.
Vaupel, P, Kallinowski, F & Okunieff, P (1989). Blood flow, oxygen and nutrient supply and metabolic microenvironment of human tumours. A review. Cancer Res 49: 6449–6465.
Warren, BA (1979). The vascular morphology of tumours. In:Tumour Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumours, Peterson HFranklin: USA 1–47.
Woods, JA, Hadfield, JA, Pettit, GR, Fox, BW & McGown, AT (1995). The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 71: 705–711.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Grosios, K., Holwell, S., McGown, A. et al. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81, 1318–1327 (1999). https://doi.org/10.1038/sj.bjc.6692174
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6692174
Keywords
This article is cited by
-
Power Doppler ultrasound and contrast-enhanced ultrasound demonstrate non-invasive tumour vascular response to anti-vascular therapy in canine cancer patients
Scientific Reports (2019)
-
Structure-Activity Relationship Studies of β-Lactam-azide Analogues as Orally Active Antitumor Agents Targeting the Tubulin Colchicine Site
Scientific Reports (2017)
-
Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling
Tumor Biology (2016)
-
Synthesis and biological evaluation of benzoxazole fused combretastatin derivatives as anticancer agents
Monatshefte für Chemie - Chemical Monthly (2016)
-
AECHL-1, a novel triterpenoid, targets tumor neo-vasculature and impairs the endothelial cell cytoskeleton
Angiogenesis (2015)
